Cutaneous Leishmaniasis in Patients under Biologic Therapies: A Spanish CLINI-AEDV Multicentre Study - PubMed
a day ago
- #Biologic Therapies
- #Cutaneous Leishmaniasis
- #Anti-TNFα
- Anti-TNFα agents are linked to reactivation of granulomatous infections like leishmaniasis.
- A retrospective study analyzed 71 patients (63 CL, 8 MCL) on biologics in an endemic area.
- Inflammatory bowel disease was the most common underlying condition (33.8%).
- Lesions were multifocal in 40% and larger than 1 cm in 94.4% of cases.
- Treatment failures were higher in MCL (50%) compared to CL (8.1%).
- Biologic therapy was discontinued in 53.5%, worsening underlying disease in 44.7%.
- No significant difference in cure rates between patients who continued vs. discontinued biologics (p=0.868).
- Findings highlight the need for standardized strategies to balance infection control and disease management.